| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.0M | +69.4% | -2.7% |
| SG&A Expense | $4.4M | -16.0% | +36.6% |
| Operating Income | -$7.3M | -5.4% | -17.5% |
| Net Income | -$6.0M | +6.8% | -46.8% |
| EPS (Basic) | -$0.33 | +36.5% | -560.0% |
| EPS (Diluted) | -$0.33 | +36.5% | -560.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $42.7M | +91.2% | — |
| Current Assets | $50.3M | +70.3% | +33.2% |
| Total Assets | $50.6M | +68.7% | +31.2% |
| Current Liabilities | $13.1M | -3.2% | +25.5% |
| Total Liabilities | $13.1M | -3.2% | +22.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$23.3M | — | — |
| Capital Expenditures | $24K | — | — |
| Investing Cash Flow | -$24K | — | — |
| Financing Cash Flow | $39.9M | — | — |
| Free Cash Flow | -$23.3M | — | — |
| $37.5M |
| +128.1% |
| +34.6% |